AKR.L Regulatory News (AKR)

Embargoed: 0700hrs 14 January 2011

Akers Biosciences, Inc.

("ABI" or the "Company")

BreathScan PRO Receives Regulatory Clearance

Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, announces that, on 12 January 2011, the BreathScan PRO alcohol detection technology received full market clearance from the United States Food and Drug Administration (FDA), including professional and over-the-counter uses. The BreathScan PRO Alcohol Detection System ("BreathScan PRO" or "System") is now available for sale throughout the USA and Europe.

The BreathScan PRO is an extension of the BreathScan product line. It merges the convenience of ABI's patented, disposable breath alcohol detectors with the quantitative precision of a digital analyser. BreathScan PRO is maintenance-free as the analyser does not require recalibration for the useful life of the unit. As a result, the System is in "test-ready" mode 24 hours a day, seven days-a-week and therefore applicable for service in a wide-range of industries including education and law enforcement, as well as numerous transportation safety programs.

The System's 3-step test procedure is easy to master and facilitates quick and reliable on-site, alcohol screenings. The System's digital analyser automatically begins processing the subject's breath sample for interpretation. BreathScan PRO then converts the breath sample into a relative Blood Alcohol Concentration (BAC) ranging from 0.000 per cent to 0.150 per cent and above. Unlike other electronic alcohol breathalysers, the System is 100% hygienic as no two subjects ever make contact with the same testing device.

Thomas A. Nicolette, Chief Executive of ABI, commented,

"Alcohol testing in legal probable cause situations is a very large existing worldwide market that we aim to capture a share of with BreathScan PRO. Our existing US distribution network and UK-based, BreathScan International Ltd. are extremely excited to add the System to their product offerings. We expect the FDA-clearance and inefficiency of existing testing procedures will open up many doors for marketing opportunities."

Enquiries:

Thomas A. Nicolette

President and CEO

Tel. +1 856 848 8698

Ben Simons

M: Communications

Tel. +44 (0)20 7920 2340

Antony Legge / Emma Earl

Daniel Stewart

Tel. +44 (0)20 7776 6550

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com